Pharmacologic and therapeutic differences among calcium channel antagonists: profile of mibefradil, a new calcium antagonist

Am J Cardiol. 1996 Nov 7;78(9A):7-12. doi: 10.1016/s0002-9149(96)00732-1.

Abstract

Calcium antagonists are a heterogeneous group of drugs, each with a different chemical structure and cardiovascular profile. Distinguishing factors include pharmacokinetics, mode of calcium mobilization affected, class and subclass of calcium channel inhibited, state-dependent interactions, and effect of disease on the drug's activity. A new calcium antagonist, mibefradil, has a unique chemical structure and cardiovascular profile compared with those currently available, and it appears to represent a new class of calcium antagonists.

Publication types

  • Review

MeSH terms

  • Animals
  • Benzimidazoles / chemistry
  • Benzimidazoles / pharmacokinetics
  • Benzimidazoles / pharmacology*
  • Benzimidazoles / therapeutic use
  • Calcium Channel Blockers / chemistry
  • Calcium Channel Blockers / pharmacokinetics
  • Calcium Channel Blockers / pharmacology*
  • Calcium Channel Blockers / therapeutic use
  • Calcium Channels / drug effects*
  • Cardiovascular System / drug effects*
  • Cell Division / drug effects*
  • Humans
  • Mibefradil
  • Muscle, Smooth / drug effects
  • Tetrahydronaphthalenes / chemistry
  • Tetrahydronaphthalenes / pharmacokinetics
  • Tetrahydronaphthalenes / pharmacology*
  • Tetrahydronaphthalenes / therapeutic use
  • Vasodilation / drug effects

Substances

  • Benzimidazoles
  • Calcium Channel Blockers
  • Calcium Channels
  • Tetrahydronaphthalenes
  • Mibefradil